LON:DNL

Diurnal Group Competitors

GBX 67.50
-0.50 (-0.74 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
67.06
68.80
50-Day Range
64
89
52-Week Range
28
97.98
Volume572,112 shs
Average Volume458,364 shs
Market Capitalization£93.38 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Diurnal Group (LON:DNL) Vs. EKF, CREO, AMYT, NCYT, TSTL, and ORPH

Should you be buying DNL stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Diurnal Group, including EKF Diagnostics (EKF), Creo Medical (CREO), Amryt Pharma (AMYT), Novacyt (NCYT), Tristel (TSTL), and Open Orphan (ORPH).

Diurnal Group (LON:DNL) and EKF Diagnostics (LON:EKF) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, earnings and profitability.

Profitability

This table compares Diurnal Group and EKF Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Diurnal GroupN/AN/AN/A
EKF DiagnosticsN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings for Diurnal Group and EKF Diagnostics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Diurnal Group0000N/A
EKF Diagnostics0000N/A

Valuation and Earnings

This table compares Diurnal Group and EKF Diagnostics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Diurnal Group£6.38 million14.64N/AGBX (4.10)-16.46
EKF Diagnostics£65.26 million4.91N/AGBX 2.4029.33

Diurnal Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Summary

EKF Diagnostics beats Diurnal Group on 3 of the 4 factors compared between the two stocks.

Diurnal Group (LON:DNL) and Creo Medical (LON:CREO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings.

Earnings & Valuation

This table compares Diurnal Group and Creo Medical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Diurnal Group£6.38 million14.64N/AGBX (4.10)-16.46
Creo Medical£8,154.0038,739.27N/AGBX (12.40)-16.13

Diurnal Group is trading at a lower price-to-earnings ratio than Creo Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Diurnal Group and Creo Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Diurnal GroupN/AN/AN/A
Creo MedicalN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for Diurnal Group and Creo Medical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Diurnal Group0000N/A
Creo Medical0000N/A

Amryt Pharma (LON:AMYT) and Diurnal Group (LON:DNL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Amryt Pharma and Diurnal Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amryt Pharma0000N/A
Diurnal Group0000N/A

Earnings & Valuation

This table compares Amryt Pharma and Diurnal Group's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amryt Pharma£186.46 million1.61N/AGBX (39.90)-4.20
Diurnal Group£6.38 million14.64N/AGBX (4.10)-16.46

Diurnal Group is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amryt Pharma and Diurnal Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amryt PharmaN/AN/AN/A
Diurnal GroupN/AN/AN/A

Novacyt (LON:NCYT) and Diurnal Group (LON:DNL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability.

Valuation and Earnings

This table compares Novacyt and Diurnal Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt£78.23 million3.78N/AGBX 51.508.14
Diurnal Group£6.38 million14.64N/AGBX (4.10)-16.46

Diurnal Group is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Novacyt and Diurnal Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NovacytN/AN/AN/A
Diurnal GroupN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for Novacyt and Diurnal Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novacyt02002.00
Diurnal Group0000N/A

Summary

Novacyt beats Diurnal Group on 3 of the 4 factors compared between the two stocks.

Tristel (LON:TSTL) and Diurnal Group (LON:DNL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Earnings and Valuation

This table compares Tristel and Diurnal Group's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£33.80 million8.01N/AGBX 11.2051.34
Diurnal Group£6.38 million14.64N/AGBX (4.10)-16.46

Diurnal Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tristel and Diurnal Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TristelN/AN/AN/A
Diurnal GroupN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Tristel and Diurnal Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tristel0000N/A
Diurnal Group0000N/A

Summary

Tristel beats Diurnal Group on 3 of the 4 factors compared between the two stocks.

Diurnal Group (LON:DNL) and Open Orphan (LON:ORPH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Valuation & Earnings

This table compares Diurnal Group and Open Orphan's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Diurnal Group£6.38 million14.64N/AGBX (4.10)-16.46
Open Orphan£10.57 million23.90N/AGBX (3.20)-11.80

Diurnal Group is trading at a lower price-to-earnings ratio than Open Orphan, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Diurnal Group and Open Orphan's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Diurnal GroupN/AN/AN/A
Open OrphanN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Diurnal Group and Open Orphan, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Diurnal Group0000N/A
Open Orphan0000N/A

Given Open Orphan's higher possible upside, analysts clearly believe Open Orphan is more favorable than Diurnal Group.

Summary

Open Orphan beats Diurnal Group on 5 of the 5 factors compared between the two stocks.


Diurnal Group Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
EKF Diagnostics logo
EKF
EKF Diagnostics
1.1$70.40-1.1%£320.32 million£65.26 million29.33Insider Selling
News Coverage
Gap Down
CREO
Creo Medical
0.5$200.00-3.0%£315.88 million£8,154.00-16.13
Amryt Pharma logo
AMYT
Amryt Pharma
0.8$167.50-3.0%£299.97 million£186.46 million-4.20Analyst Report
High Trading Volume
News Coverage
NCYT
Novacyt
0.6$419.20-1.6%£296.06 million£78.23 million8.14
Tristel logo
TSTL
Tristel
0.6$575.00-0.9%£270.61 million£33.80 million51.34
ORPH
Open Orphan
0.0$37.75-1.3%£252.70 million£10.57 million-11.80
ARIX
Arix Bioscience
0.8$189.50-0.3%£252.69 million£135.77 million2.14
ECO Animal Health Group logo
EAH
ECO Animal Health Group
0.9$362.50-0.0%£245.43 million£86.32 million72.50Gap Down
ANGLE logo
AGL
ANGLE
0.4$113.50-0.0%£244.54 million£762,000.00-17.46
Bioventix logo
BVXP
Bioventix
0.8$4,160.00-0.0%£216.69 million£10.38 million31.71
Synairgen logo
SNG
Synairgen
0.4$105.10-4.7%£210.11 million£79,000.00-20.61
MGP
Medica Group
0.8$160.00-0.3%£195.83 million£41.55 million36.36High Trading Volume
POLX
Polarean Imaging
0.5$92.00-3.3%£192.31 million£2.23 million-27.06Gap Down
DDDD
4D pharma
0.6$102.60-0.6%£184.99 million£690,000.00-5.32
Redx Pharma logo
REDX
Redx Pharma
0.6$65.00-0.0%£178.03 million£5.69 million-12.04Gap Down
ANIC
Agronomics
0.5$35.00-2.9%£175.66 million£1.05 million-175.00Gap Down
Scancell logo
SCLP
Scancell
0.6$21.25-1.6%£173.23 millionN/A-15.18
Faron Pharmaceuticals Oy logo
FARN
Faron Pharmaceuticals Oy
0.6$333.90-1.2%£168.48 million£2.12 million-10.34
ANCR
Animalcare Group
0.5$275.00-0.4%£165.16 million£70.49 million687.50
ONC
Oncimmune
0.4$236.00-1.3%£163.07 million£2.03 million-25.93Gap Down
Tiziana Life Sciences logo
TILS
Tiziana Life Sciences
0.4$81.50-0.0%£158.61 millionN/A-14.82Gap Up
Omega Diagnostics Group logo
ODX
Omega Diagnostics Group
0.3$84.00-1.2%£153.38 million£8.52 million-19.09High Trading Volume
Mereo BioPharma Group plc (MPH.L) logo
MPH
Mereo BioPharma Group plc (MPH.L)
0.6N/AN/A£138.87 millionN/A-0.21News Coverage
Gap Down
Allergy Therapeutics logo
AGY
Allergy Therapeutics
0.9$21.60-0.0%£138.41 million£81.76 million21.60News Coverage
SBI
Sourcebio International
1.7$175.00-2.9%£129.82 millionN/A0.00Gap Down
Circassia Group logo
CIR
Circassia Group
0.9$31.00-3.2%£129.64 million£23.90 million-3.52Gap Up
VSN
Verseon
0.5N/AN/A£127.41 millionN/A-5.17Gap Up
Advanced Oncotherapy logo
AVO
Advanced Oncotherapy
0.4$35.90-0.3%£125.44 millionN/A-3.66News Coverage
ETX
e-therapeutics
0.4$29.25-0.2%£123.08 million£305,000.00-29.25
Futura Medical logo
FUM
Futura Medical
1.5$46.50-1.1%£119.04 million£31,778.00-46.50Gap Up
Verona Pharma plc (VRP.L) logo
VRP
Verona Pharma plc (VRP.L)
0.5$26.15-0.2%£108.40 millionN/A-0.80High Trading Volume
Venture Life Group logo
VLG
Venture Life Group
0.7$85.50-0.0%£107.59 million£30.08 million34.20News Coverage
DXRX
Diaceutics
0.5$125.50-0.0%£105.51 million£12.70 million418.33Insider Selling
Shield Therapeutics logo
STX
Shield Therapeutics
0.9$48.00-1.3%£103.60 million£10.39 million-21.82News Coverage
YGEN
Yourgene Health
0.7$14.25-7.0%£103.05 million£17.03 million-23.75Gap Down
SBTX
SkinBioTherapeutics
0.4$62.00-3.9%£97.20 millionN/A-62.00
VRCI
Verici Dx
0.0$67.50-0.7%£95.68 millionN/A0.00News Coverage
C4XD
C4X Discovery
0.6$41.50-9.0%£93.93 million£7.06 million-7.83Gap Down
SIS
Science in Sport
0.9$68.50-1.3%£92.54 million£50.35 million-52.69News Coverage
Georgia Healthcare Group PLC (GHG.L) logo
GHG
Georgia Healthcare Group PLC (GHG.L)
0.8N/AN/A£91.67 millionN/A0.00
Destiny Pharma logo
DEST
Destiny Pharma
0.8$142.50-2.1%£85.30 million£12,450.00-11.88
ReNeuron Group logo
RENE
ReNeuron Group
0.6$147.50-0.7%£83.86 million£112,000.00-3.21
IHC
Inspiration Healthcare Group
0.9$123.00-1.2%£83.79 million£36.98 million24.12News Coverage
Gap Up
Immunodiagnostic Systems logo
IDH
Immunodiagnostic Systems
0.5$270.00-0.7%£77.72 million£34.25 million207.69News Coverage
SAR
Sareum Holdings plc (SAR.L)
0.5$2.25-0.9%£73.52 million£47,204.00-7.15
OBD
Oxford BioDynamics
0.5$78.10-0.5%£72.29 million£456,000.00-16.62
TLY
Totally
1.3$39.25-0.6%£71.52 million£110.83 million-196.25
Kromek Group logo
KMK
Kromek Group
0.5$15.75-2.9%£68.02 million£12.36 million-3.15
ABDX
Abingdon Health
0.3$55.77-0.4%£53.59 millionN/A0.00Gap Up
IUG
Diurnal Group
0.0$18.50-0.1%£49.84 million£5.17 million-14.23High Trading Volume
This page was last updated on 5/9/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.